Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer

BACKGROUND: Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life‐threatening adverse event. The purpose of this study was to evaluate whether the development of immune‐related adverse events (irAEs), especially ILD, was associated with treatment effica...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Thorac Cancer
Egile Nagusiak: Sugano, Teppei, Seike, Masahiro, Saito, Yoshinobu, Kashiwada, Takeru, Terasaki, Yasuhiro, Takano, Natsuki, Hisakane, Kakeru, Takahashi, Satoshi, Tanaka, Toru, Takeuchi, Susumu, Miyanaga, Akihiko, Minegishi, Yuji, Noro, Rintaro, Kubota, Kaoru, Gemma, Akihiko
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons Australia, Ltd 2020
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7113045/
https://ncbi.nlm.nih.gov/pubmed/32096610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13364
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak